trending Market Intelligence /marketintelligence/en/news-insights/trending/I0efyZfbCuNuLPlu4JBydQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

RegeneRx to receive EU patent for neural injury drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


RegeneRx to receive EU patent for neural injury drug

RegeneRx Biopharmaceuticals Inc.'s neural injury drug RGN-352 is set to receive patent protection in Europe.

The European Patent Office notified the company of its intent to grant patent protection through March 26, 2030.